This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): folate-hapten conjugate, folate-FITC
Description: EC17 is a folate-targeted hapten immunotherapy drug. Treatment consists of vaccination with EC90 (a KLH-FITC conjugate) and GPI-0100 adjuvant, followed by dosing with EC17 (folate-FITC conjugate) in combination with low-dose cytokines. The folate-FITC targets to folate-expressing cancer cells, while the KLH-FITC conjugate raises an immune response to FITC, a fluorescent small-molecule dye. By marking tumor cells with millions of folate receptor-targeted hapten, EC17 allows the body’s immune system to recognize and eliminate the cancerous cells.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet Global Pharma Guidance Tracker – April 2019
Additional information available to subscribers only: